T-lymphocytes that have been engineered to express a modified antigen-specific T-cell receptor (TCR). In cancer therapy, the TCR-engineered T-cell recognizes a tumor-specific protein fragment complexed with major histocompatibility complex (MHC) molecules on the surface of the tumor cells and kills the tumor cell. [ ]